Actinium Pharmaceuticals (ATNM) Gets a Buy Rating from William Blair

By Austin Angelo

In a report issued on November 4, Andy Hsieh from William Blair reiterated a Buy rating on Actinium Pharmaceuticals (ATNMResearch Report). The company’s shares closed last Thursday at $10.40.

According to, Hsieh is a 4-star analyst with an average return of 14.7% and a 56.3% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Nektar Therapeutics, and Seattle Genetics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $38.75 average price target, a 263.8% upside from current levels. In a report issued on November 5, Alliance Global Partners also initiated coverage with a Buy rating on the stock with a $25.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.47 and a one-year low of $4.71. Currently, Actinium Pharmaceuticals has an average volume of 429.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.